Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan

References

• Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the common neurologic disorders? Neurology. 2007;68:326–337.
   PubMed Web of Science ®Google Scholar
• Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–39.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Non-motor parkinsonism. Parkinsonism Relat Disord. 2007;13:S211–S220.
   PubMed Web of Science ®Google Scholar
• Davie CA. A review of Parkinson's disease. Br Med Bull. 2008;86:109–127.
   PubMed Web of Science ®Google Scholar
• Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun. 2004;18:407–413.
   PubMed Web of Science ®Google Scholar
• Pasqualetti G, Brooks DJ, Edison P. The role of neuroinflammation in dementias. Curr Neurol Neurosci Rep. 2015;15:17.
   PubMed Web of Science ®Google Scholar
• Kogure T, Tatsumi T, Yuka K, et al. Rheumatoid arthritis accompanied by Parkinson disease. J Clin Rheumatol. 2008;14:192–193.
   PubMed Web of Science ®Google Scholar
• Kunas RC, McRae A, Kesselring J, et al. Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson’s disease. J Allergy Clin Immunol. 1995;96:688–690.
   PubMed Web of Science ®Google Scholar
• García-Moreno JM, Chaco´n J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov Disord. 2002;17:1329–1335.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994;180:147–150.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Riederer P, et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208–210.
   PubMed Web of Science ®Google Scholar
• Mogi M, Kondo T, Mizuno Y, et al. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the Parkinsonian brain. Neurosci Lett. 2007;414:94–97.
   PubMed Web of Science ®Google Scholar
• Chen H, O’Reilly EJ, Schwarzschild MA, et al. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008;167:90–95.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang SM, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059–1064.
   PubMed Web of Science ®Google Scholar
• Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005;58:963–967.
   PubMed Web of Science ®Google Scholar
• Wahner AD, Bronstein JM, Bordelon YM, et al. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 2007;69:1836–1842.
   PubMed Web of Science ®Google Scholar
• Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver section. JAMA. 2012;308:1906–1914.
   PubMed Web of Science ®Google Scholar
• Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population based study. Ann Rheum Dis. 2010;69:1165–1168.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015;175:1518–1526.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Valdes AM, et al. Familial risk of Sjögren’s syndrome and co-aggregation of autoimmune diseases in affected families: a nationwide population study. Arthritis Rheumatol. 2015;67:1904–1912.
   PubMed Web of Science ®Google Scholar
• Yen YF, Chuang PH, Jen IA, et al. Incidence of autoimmune diseases in a nationwide HIV/AIDS patient cohort in Taiwan, 2000–2012. Ann Rheum Dis. 2016;0:1–5.
   Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324.
   PubMed Web of Science ®Google Scholar
• American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–590.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–558.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–407.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–347.
   PubMed Web of Science ®Google Scholar
• International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
   PubMed Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122–1128.
   PubMed Web of Science ®Google Scholar
• Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990.33:1101–1107.
   Google Scholar
• Arend WP1, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129–1134.
   PubMed Web of Science ®Google Scholar
• Rugbjerg K, Friis S, Ritz B, et al. Autoimmune disease and risk for Parkinson disease: a population-based case-control study. Neurology. 2009;73:1462–1468.
   PubMed Web of Science ®Google Scholar
• Figueiredo-Pereira ME, Rockwell P, Schmidt-Glenewinkel T, et al. Neuroinflammation and J2 prostaglandins: linking impairment of the ubiquitin-proteasome pathway and mitochondria to neurodegeneration. Front Mol Neurosci. 2015;7:104.
   PubMed Web of Science ®Google Scholar
• Moehle MS, West AB. M1 and M2 immune activation in Parkinson's Disease: Foe and ally? Neuroscience. 2014;302:59–73.
   PubMed Web of Science ®Google Scholar
• Prajapati P, Sripada L, Singh K, et al. TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells. Biochim Biophys Acta. 2014;1852:451–461.
   PubMed Web of Science ®Google Scholar
• Visser LH, Koudstaal PJ, van de Merwe JP. Hemiparkinsonism in a patient with primary Sjogren’s syndrome. Case report and a review of the literature. Clin Neurol Neurosurg. 1993;95:141–145.
   PubMed Web of Science ®Google Scholar
• Walker RH, Spiera H, Brin MF, et al. Parkinsonism associated with Sjögren's syndrome: three cases and a review of the literature. Mov Disord. 1999;14:262–268.
   PubMed Web of Science ®Google Scholar
• Hassin-Baer S, Levy Y, Langevitz P, et al. glycoprotein I in Sjogren’s syndrome is associatedwith parkinsonism. Clin Rheumatol. 2007;26:743–747.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184.
   PubMed Web of Science ®Google Scholar
• Ertan S, Fresko I, Apaydin H, et al. Extrapyramidal type rigidity in rheumatoid arthritis. Rheumatology (Oxford). 1999;38:627–630.
   PubMed Web of Science ®Google Scholar
• Akiyama H, Itagaki S, McGeer PL. Major histocompatibility complex antigen expression on rat microglia following epidural kainic acid lesions. J Neurosci Res. 1988;20:147–157.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Kondo T, et al. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson’s disease. J Neural Transm Gen Sect. 1995;9:87–92.
   Web of Science ®Google Scholar
• Hartmann A, Hunot S, Hirsch EC. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp Neurol. 2003;184:561–564.
   PubMed Web of Science ®Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–1108.
   PubMed Web of Science ®Google Scholar
• Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010;120:277–286.
   PubMed Web of Science ®Google Scholar
• Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007;208:1–25.
   PubMed Web of Science ®Google Scholar
• Kones R. Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and herapeutic neuroprotective nutrition. Nutr Clin Pract. 2010;25:371–389.
   PubMed Web of Science ®Google Scholar
• Schiess M. Non- steroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arch Neurol. 2003;60:1043–104.
   Google Scholar
• Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA. 2003;100:5473–5478.
   PubMed Web of Science ®Google Scholar
• Grilli M, Pizzi M, Memo M, et al. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science. 1996;274:1383–1385.
   PubMed Web of Science ®Google Scholar
• Adelman DC, Saltiel E, Klinenberg JR. The neuropsychiatric manifestations of systemic lupus erythematosus. Semin Arthritis Rheum. 1986;15:185–199.
   PubMed Web of Science ®Google Scholar
• Moore PM, Lisak RP. Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction. Springer Semin Immunopathol. 1995;17:43–60.
   PubMed Web of Science ®Google Scholar
• Liu FC, Huang WY, Lin TY, et al. Inverse association of Parkinson disease with systemic lupus erythematosus: a nationwide population-based study. Medicine (Baltimore). 2015;94:e2097.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Adami HO, Cole P, et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26(Suppl. 1):S1–S58.
   PubMed Web of Science ®Google Scholar